Published in Am J Transl Res on April 19, 2013
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. J Transl Med (2015) 0.89
A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model. PLoS One (2014) 0.85
Evaluation of ERG responsive proteome in prostate cancer. Prostate (2013) 0.83
miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1. Oncotarget (2015) 0.81
Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer. Int J Clin Exp Pathol (2015) 0.80
Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition. Biochem Soc Trans (2014) 0.80
ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. Mol Clin Oncol (2014) 0.79
Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC Cancer (2014) 0.79
Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. Genes Cancer (2014) 0.79
ETS transcription factors in embryonic vascular development. Angiogenesis (2016) 0.79
A simple, rapid, low-cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA. Sci Rep (2016) 0.75
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. Genes Cancer (2016) 0.75
DNA microstructure influences selective binding of small molecules designed to target mixed-site DNA sequences. Nucleic Acids Res (2017) 0.75
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J (2010) 4.78
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res (2006) 4.50
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol (2008) 3.07
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther (2007) 2.97
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem (2011) 2.89
Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer (2006) 2.69
Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol (2007) 2.68
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol (2007) 2.47
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia (2006) 2.39
TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology (2007) 2.28
ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis (2010) 2.24
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 2.18
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
The role of Osteopontin in tumor metastasis. J Surg Res (2004) 2.03
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03
Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood (2008) 2.00
Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci (2006) 1.96
FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2010) 1.88
Erg is required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice. Blood (2011) 1.69
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. Cancer Res (2008) 1.68
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68
Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci (2008) 1.67
The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta (2006) 1.60
ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biol Ther (2011) 1.56
Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation (2008) 1.55
Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep (2007) 1.43
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol (2011) 1.36
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One (2010) 1.35
Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res (2008) 1.35
Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res (2003) 1.35
ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. Genes Dev (2011) 1.30
TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol (2010) 1.23
Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation. Blood (2001) 1.21
ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol (2010) 1.21
Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res (2010) 1.18
Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer (2010) 1.18
Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology (2012) 1.16
TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One (2011) 1.15
A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS One (2008) 1.14
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol (2011) 1.12
Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res (2010) 1.09
YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS One (2011) 1.07
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget (2011) 1.07
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res (2012) 1.05
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am J Clin Pathol (2012) 1.05
Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol (2012) 1.02
Molecular markers of prostate cancer. Urol Oncol (2006) 1.00
Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate (2008) 1.00
Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells. Transl Oncol (2010) 0.99
Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res (2011) 0.97
Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. J Cancer (2010) 0.97
Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res (2012) 0.95
Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One (2011) 0.94
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PLoS One (2011) 0.93
Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. Oncogene (2011) 0.90
Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin. Mol Cancer Res (2011) 0.88
The clinical relevance of molecular genetics in soft tissue sarcomas. Adv Anat Pathol (2010) 0.87
The multi-disciplinary management of high-risk prostate cancer. Urol Oncol (2009) 0.86
Tetrasomy of Philadelphia chromosome in myeloblastic crisis of chronic myelogenous leukemia. Int J Hematol (1995) 0.76
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med (2009) 2.17
Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest (2010) 1.73
GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem (2009) 1.56
Wnt-3a-dependent cell motility involves RhoA activation and is specifically regulated by dishevelled-2. J Biol Chem (2004) 1.43
Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res (2006) 1.32
Predicting new indications for approved drugs using a proteochemometric method. J Med Chem (2012) 1.29
Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol (2008) 1.27
Disulfide bond assignments of secreted Frizzled-related protein-1 provide insights about Frizzled homology and netrin modules. J Biol Chem (2001) 1.10
Wnt signaling promotes proliferation and stemness regulation of spermatogonial stem/progenitor cells. Reproduction (2009) 1.09
Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer (2008) 1.04
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. Oncogene (2005) 1.03
N-terminal extension of N-methylpurine DNA glycosylase is required for turnover in hypoxanthine excision reaction. J Biol Chem (2007) 0.97
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell (2012) 0.95
Development of a novel assay for human tyrosyl DNA phosphodiesterase 2. Anal Biochem (2011) 0.93
A global benchmark study using affinity-based biosensors. Anal Biochem (2008) 0.91
Excised damaged base determines the turnover of human N-methylpurine-DNA glycosylase. DNA Repair (Amst) (2009) 0.90
The ezrin metastatic phenotype is associated with the initiation of protein translation. Neoplasia (2012) 0.89
The E6 oncoprotein from HPV16 enhances the canonical Wnt/β-catenin pathway in skin epidermis in vivo. Mol Cancer Res (2011) 0.87
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther (2011) 0.86
1E7-03, a low MW compound targeting host protein phosphatase-1, inhibits HIV-1 transcription. Br J Pharmacol (2014) 0.86
Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One (2012) 0.86
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget (2014) 0.85
Expression, purification and characterization of codon-optimized human N-methylpurine-DNA glycosylase from Escherichia coli. Protein Expr Purif (2007) 0.85
Characterization of magnesium requirement of human 5'-tyrosyl DNA phosphodiesterase mediated reaction. BMC Res Notes (2012) 0.84
Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo. Cancer Res (2006) 0.84
A new era for an ancient drug: arsenic trioxide and Hedgehog signaling. Vitam Horm (2012) 0.84
A comparative study of recombinant mouse and human apurinic/apyrimidinic endonuclease. Mol Cell Biochem (2011) 0.83
Binding kinetics and activity of human poly(ADP-ribose) polymerase-1 on oligo-deoxyribonucleotide substrates. J Mol Recognit (2009) 0.83
Acetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity. Front Oncol (2012) 0.82
Dipole-dipole interaction stabilizes the transition state of apurinic/apyrimidinic endonuclease--abasic site interaction. J Biol Chem (2007) 0.82
Identification of a peptide binding motif for secreted frizzled-related protein-1. Peptides (2004) 0.81
Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma. Clin Orthop Relat Res (2014) 0.81
Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue. Virology (2013) 0.80
Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature. Sarcoma (2013) 0.80
Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1. Exp Cell Res (2012) 0.77